Observation program “Application of modern insulin therapy approaches
for patients with type 2 diabetes” as a part of Rinsulin delivery was
launched in Moscow. The aim of the program is to prove the efficiency
and safety of Rinsulin during primary administration and in case of
switching from other genetically engineered insulins.
In Moscow Rinsulin became available for patients with diabetes receiving preferential provision since 2015.
Studies will be conducted between April and November 2015. 400
patients from all districts of Moscow will participate in them. It is
important to note that study design is based on daily actual practice of
endocrinologists and is as close to reality as possible.
The study includes glycemic level monitoring associated with Rinsulin
administration. Glycemic level evaluation is conducted using Contour TS
glucometers manufactured by Bayer http://diabetes.bayer.ru/contour_ts/.
It is one of the world leading manufacturers of BSL measuring
equipment. The study is relevant because despite the creation of new
insulin analogues modifications, human insulin drugs are still used (by
about 40% of all patients receiving insulin therapy in Moscow) and
provide safe and effective control of HbA1c index. Due to their rational
cost, human insulin drugs provide healthcare services an opportunity to
purchase additional medical products and costly innovative drugs
Rinsulin® R and Rinsulin® NPH are manufactured by GEROPHARM-Bio using full cycle principle - from substance to finished dosage form. Full cycle technology allows to manufacture insulin of highest purity. These days drugs are available in all modern product (vials, cartridges) and delivery forms (pre-filled insulin pens).